{"disease":{"id":"jak2-v617","name":"jak2 v617"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05198960","title":"AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1308,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT04994158","title":"MASCOT Registry of Patients With Myeloproliferative Neoplasms Associated Splanchnic Vein Thrombosis","phase":"","overall_status":"COMPLETED","enrollment_count":238,"lead_sponsor_name":"Royal Free Hospital NHS Foundation Trust","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}